Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase01:27

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

91
Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
91
Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

1.0K
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
1.0K
Antiepileptic Drugs: GABAergic Pathway Potentiators01:18

Antiepileptic Drugs: GABAergic Pathway Potentiators

1.7K
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
1.7K
Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance01:23

Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance

912
The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...
912
Urinary Tract Calculi III: Medical Management01:30

Urinary Tract Calculi III: Medical Management

389
The diagnosis of renal calculi involves several imaging techniques, including non-contrast CT scans and ultrasound. These methods help visualize kidney stones, assess their size and location, and detect possible obstructions. Additionally, Measuring urine pH is useful for diagnosing specific stone types, such as struvite (alkaline pH) and uric acid stones (acidic pH). Cystine stones are primarily linked to cystinuria, a genetic condition. A urinalysis helps detect blood in the urine (hematuria)...
389
Renal Failure: Dose Adjustments01:11

Renal Failure: Dose Adjustments

660
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
660

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A Latent Class Analysis of COVID-19 Vaccine Attitudes and Beliefs: Results from a Community Survey Conducted Via the Chicagoland Community Engagement Alliance (CEAL) Program.

Journal of community health·2025
Same author

Engaging the private sector as part of HIV pre-exposure prophylaxis service delivery in Vietnam: a comparative analysis of uptake, persistence and HIV seroconversion from 2018 to 2023.

Frontiers in reproductive health·2025
Same author

DOT1L maintains NK cell phenotype and function for optimal tumor control.

Cell reports·2024
Same author

Investigating the acceptability of a culturally adapted acceptance and commitment therapy group for UK Vietnamese communities: A practice-based feasibility study.

Transcultural psychiatry·2024
Same author

Generation and multi-dimensional profiling of a childhood cancer cell line atlas defines new therapeutic opportunities.

Cancer cell·2023
Same author

MED12 and BRD4 cooperate to sustain cancer growth upon loss of mediator kinase.

Molecular cell·2021

Related Experiment Video

Updated: Apr 21, 2026

Quantitative SERS Detection of Uric Acid via Formation of Precise Plasmonic Nanojunctions within Aggregates of Gold Nanoparticles and Cucurbit[n]uril
10:02

Quantitative SERS Detection of Uric Acid via Formation of Precise Plasmonic Nanojunctions within Aggregates of Gold Nanoparticles and Cucurbit[n]uril

Published on: October 3, 2020

3.6K

Pyrazinamide-induced hyperuricemia.

Antony Q Pham, Anh Doan, Matt Andersen

    P & T : a Peer-Reviewed Journal for Formulary Management
    |October 23, 2014
    PubMed
    Summary
    This summary is machine-generated.

    High uric acid can cause crystal deposition, leading to gout and kidney issues. This case study links elevated uric acid and hyperuricemia to the tuberculosis drug pyrazinamide in a 34-year-old male.

    More Related Videos

    Optimized Griess Reaction for UV-Vis and Naked-eye Determination of Anti-malarial Primaquine
    08:31

    Optimized Griess Reaction for UV-Vis and Naked-eye Determination of Anti-malarial Primaquine

    Published on: October 11, 2019

    9.0K
    Microwave-Assisted Preparation of 1-Aryl-1H-pyrazole-5-amines
    05:07

    Microwave-Assisted Preparation of 1-Aryl-1H-pyrazole-5-amines

    Published on: June 23, 2019

    6.2K

    Related Experiment Videos

    Last Updated: Apr 21, 2026

    Quantitative SERS Detection of Uric Acid via Formation of Precise Plasmonic Nanojunctions within Aggregates of Gold Nanoparticles and Cucurbit[n]uril
    10:02

    Quantitative SERS Detection of Uric Acid via Formation of Precise Plasmonic Nanojunctions within Aggregates of Gold Nanoparticles and Cucurbit[n]uril

    Published on: October 3, 2020

    3.6K
    Optimized Griess Reaction for UV-Vis and Naked-eye Determination of Anti-malarial Primaquine
    08:31

    Optimized Griess Reaction for UV-Vis and Naked-eye Determination of Anti-malarial Primaquine

    Published on: October 11, 2019

    9.0K
    Microwave-Assisted Preparation of 1-Aryl-1H-pyrazole-5-amines
    05:07

    Microwave-Assisted Preparation of 1-Aryl-1H-pyrazole-5-amines

    Published on: June 23, 2019

    6.2K

    Area of Science:

    • Nephrology
    • Pharmacology
    • Rheumatology

    Background:

    • Elevated uric acid levels (hyperuricemia) are linked to crystal deposition diseases.
    • Conditions associated with hyperuricemia include gout, urolithiasis, and urate nephropathy.
    • Antitubercular drugs are essential but can have adverse effects.

    Purpose of the Study:

    • To report a case of hyperuricemia associated with pyrazinamide use.
    • To highlight the potential renal and metabolic complications of pyrazinamide.
    • To increase awareness among clinicians regarding drug-induced hyperuricemia.

    Main Methods:

    • Case report of a 34-year-old male patient.
    • Review of patient's medical history and medication.
    • Analysis of uric acid levels in relation to pyrazinamide treatment.

    Main Results:

    • The patient presented with hyperuricemia.
    • The hyperuricemia was temporally associated with the initiation of pyrazinamide therapy.
    • No other clear cause for hyperuricemia was identified.

    Conclusions:

    • Pyrazinamide, an antitubercular medication, may cause or exacerbate hyperuricemia.
    • Clinicians should monitor uric acid levels in patients treated with pyrazinamide.
    • This association underscores the importance of pharmacovigilance for antitubercular drugs.